Halia Therapeutics, Inc.
Halia Therapeutics is a biopharmaceutical company focused on revolutionizing chronic inflammation therapy by studying individuals with genetic resilience. Their approach decodes natural disease resistance to identify protective biological mechanisms, leading to the development of novel drug targets and safer, more effective therapies. The company utilizes its proprietary GENMOR platform, enhanced by AI (GENMOR-AI), to analyze genetic and health data, accelerating the discovery of human-validated targets. Halia has advanced drug candidates for Alzheimer's disease, myelodysplastic syndrome (MDS), and obesity, which are currently in clinical trials. They aim to create a future where longevity and vitality are improved by harnessing genetic resilience.
Halia Therapeutics, Inc.
Halia Therapeutics is a biopharmaceutical company focused on revolutionizing chronic inflammation therapy by studying individuals with genetic resilience. Their approach decodes natural disease resistance to identify protective biological mechanisms, leading to the development of novel drug targets and safer, more effective therapies. The company utilizes its proprietary GENMOR platform, enhanced by AI (GENMOR-AI), to analyze genetic and health data, accelerating the discovery of human-validated targets. Halia has advanced drug candidates for Alzheimer's disease, myelodysplastic syndrome (MDS), and obesity, which are currently in clinical trials. They aim to create a future where longevity and vitality are improved by harnessing genetic resilience.